These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11562773)

  • 41. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
    Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
    J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
    España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
    Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.
    Pasupuleti N; Grodzki AC; Gorin F
    Mol Pharmacol; 2015 Apr; 87(4):683-96. PubMed ID: 25634671
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
    Zeslawska E; Schweinitz A; Karcher A; Sondermann P; Sperl S; Stürzebecher J; Jacob U
    J Mol Biol; 2000 Aug; 301(2):465-75. PubMed ID: 10926521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1H NMR characterization of the urokinase kringle module. Structural, but not functional, relatedness to homologous domains.
    Bokman AM; Jiménez-Barbero J; Llinás M
    J Biol Chem; 1993 Jul; 268(19):13858-68. PubMed ID: 8314753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
    Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topology of an amiloride-binding protein.
    Lin C; Kieber-Emmons T; Villalobos AP; Foster MH; Wahlgren C; Kleyman TR
    J Biol Chem; 1994 Jan; 269(4):2805-13. PubMed ID: 8300613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
    Massey AP; Harley WR; Pasupuleti N; Gorin FA; Nantz MH
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2635-9. PubMed ID: 22366654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
    Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
    Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
    El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
    Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defining topological similarities among ion transport proteins with anti-amiloride antibodies.
    Kieber-Emmons T; Lin C; Prammer KV; Villalobos A; Kosari F; Kleyman TR
    Kidney Int; 1995 Oct; 48(4):956-64. PubMed ID: 8569105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
    Solis-Calero C; Zanatta G; Pessoa CDÓ; Carvalho HF; Freire VN
    Phys Chem Chem Phys; 2018 Sep; 20(35):22818-22830. PubMed ID: 30151512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
    Nienaber V; Wang J; Davidson D; Henkin J
    J Biol Chem; 2000 Mar; 275(10):7239-48. PubMed ID: 10702294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.